Sionna Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.78 USD (Oct 30, 2026, 2:41 PM EDT) · Market cap 170.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Details
| Name | Sionna Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 59 |
| Founded | 2019 |
| Ipo Date | 2025-02-07 |
| Ceo | Michael Cloonan |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US8294011080 |
| Cusip | 829401108 |
| Cik | 2036042 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Michael Cloonan M.B.A. | President, Chief Executive Officer and Director |
| Elena H. Ridloff C.F.A. | Chief Financial Officer and Chief Business Officer |
| Dr. Greg Hurlbut Ph.D. | Co-Founder and Senior Vice President of Discovery Research |
| Dr. Mark Munson Ph.D. | Co-founder |
| Andy Chu | Vice President of Information and Technology |
| Juliet Labadorf | Senior Director of Investor Relations and Corporate Development |
| Jennifer Fitzpatrick J.D. | Chief Legal Officer and Head of Program Management |
| Roxanne McGrath | Vice President of Head of Human Resources |
| Dr. Charlotte McKee M.D. | Chief Medical Officer and Head of Research and Development |
| Mara Furlow M.S. | Senior Vice President of Global Regulatory Affairs and Quality |
Contact
| Address | 21 Hickory Drive, Suite 500, Waltham, Massachusetts 02451, United States |
| Phone | 617 819 2020 |
| Website | https://www.sionnatx.com |